Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.

Launched by SAMSUNG MEDICAL CENTER · Jul 6, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how a new type of medicine called a potassium competitive acid blocker (P-CAB) works for protecting the stomach in people who have heart problems and have had a procedure called percutaneous coronary intervention (PCI). This procedure helps open blocked heart arteries. After PCI, patients usually take two blood-thinning medicines to prevent clots, but these can sometimes cause stomach problems like bleeding. The study wants to see if P-CAB is safe and effective for protecting the stomach in these patients.

People who might join the study are adults between 65 and 74 years old who have had PCI and are taking two specific blood thinners along with aspirin. They should not have used stomach acid medicines like P-CAB, proton pump inhibitors (PPIs), or H2 blockers in the past month. Participants will be monitored to see how well P-CAB protects their stomach and if it causes any side effects while they continue their heart medications. This study is still recruiting volunteers, so if you fit the criteria and are interested, you can talk to your doctor about joining.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who underwent PCI
• • Use of either clopidogrel, prasugrel, or ticagrelor in combination with aspirin
• • No use of PCAB, PPI, or an H2-receptor within the past month
• Exclusion Criteria:
• • Patients with low GI bleeding risk are taken on PPI
• • Patients with high GI bleeding risk do not take PPI